DeepCure Presents Laparoscopic RDN Research Results at CRT 2025
DeepQure, a company specializing in laparoscopic renal denervation (RDN) devices, announced on the 10th that it participated in the Cardiovascular Research Technology (CRT) conference 'CRT 2025' held in Washington, D.C., USA on the 8th.
CRT 2025 is a globally renowned academic conference in cardiovascular research and treatment. It will be held from the 8th to the 11th at the Washington Hilton Hotel in Washington, D.C.
This conference serves as a crucial platform for sharing the latest research findings and treatment technologies in cardiovascular disease. It brings together medical professionals, researchers, and industry professionals from around the world to exchange knowledge and collaborate. It plays a crucial role in promoting innovative research and clinical applications, particularly in the cardiovascular field.
At this conference, DeepQure presented a paper titled "Twenty-Four Week Safety and Efficacy of a Novel Extravascular Renal Denervation Device in a Porcine Model at an Elevated Temperature Setting." Professor Chang-Wook Jeong, founder of DeepCure and a professor at Seoul National University Hospital, co-authored the study.
The presenter was Dr. Abraham R. Tzafriri, Director of Research and Innovation at the Center for Biomedical Science and Engineering Technology (CBSET), the US-based animal testing facility where DeepCure conducted its large-animal preclinical trials.
A DeepQure representative stated, “Through our participation in this CRT conference, we were able to present the safety and effectiveness of our laparoscopic RDN device to medical professionals around the world,” and added, “We will continue to raise Hypercure’s profile and promote our technological differentiation by presenting important research results.”
Meanwhile, DeepQure's HyperQure is the world's first laparoscopic RDN device for treating resistant hypertension. It is a Class III FDA medical device and is currently undergoing clinical trials for its first premarket approval (PMA) in Korea.